Follow us on Twitter
twitter icon@FreshPatents

Autoimmune Diseases patents

      

This page is updated frequently with new Autoimmune Diseases-related patent applications.




 Antibody therapeutics that bind cd137 patent thumbnailnew patent Antibody therapeutics that bind cd137
There is disclosed compositions and methods relating to or derived from anti-cd137 antibodies. More specifically, there is disclosed fully human antibodies that bind cd137, cd137-antibody binding fragments and derivatives of such antibodies, and cd137-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.


 T cell activation inhibitor, pharmaceutical composition containing same, and screening  t cell activation inhibiting substance patent thumbnailnew patent T cell activation inhibitor, pharmaceutical composition containing same, and screening t cell activation inhibiting substance
Provided is a t cell activation inhibitor containing an rgm inhibiting substance such as an anti-rgm neutralizing antibody and the like as an active ingredient. The t cell activation inhibitor is useful as a pharmaceutical composition for the prophylaxis or treatment of autoimmune diseases such as multiple sclerosis and the like, and other diseases caused by t cell activation.
Mitsubishi Tanabe Pharma Corporation


 Superkines and synthekines:  repurposed cytokines with new and enhanced signaling activities patent thumbnailnew patent Superkines and synthekines: repurposed cytokines with new and enhanced signaling activities
Disclosed herein are il-4 cytokine compositions with enhanced biological activity having increased selectivity for il-4 cytokine receptors, and methods for their use. These compositions encompass interleukin-4 (il-4) muteins.

 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders patent thumbnailnew patent Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
Wherein r1a, r1b, r2, r4, r5, r6a, r6b, r7, r8, w, x, cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (npp2 or enpp2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention..

 Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders. patent thumbnailnew patent Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders.
The present invention relates to novel compounds according to formula i that antagonize gpr84, a g-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (ibd), rheumatoid arthritis, vasculitis, lung diseases (e.g. Chronic obstructive pulmonary disease (copd) and lung interstitial diseases (e.g.

 Fused heterocyclic compound, preparation method therefor, pharmaceutcial composition, and uses thereof patent thumbnailnew patent Fused heterocyclic compound, preparation method therefor, pharmaceutcial composition, and uses thereof
Disclosed are a fused heterocyclic compound, a preparation method therefor, a pharmaceutical composition, and uses thereof. The fused heterocyclic compound is shown in formula i, formula ii, or formula iii.
Shanghai Yingli Pharmaceutical Co., Ltd.


 New pi3k/akt/mtor inhibitors and pharmaceutical uses thereof patent thumbnailnew patent New pi3k/akt/mtor inhibitors and pharmaceutical uses thereof
The invention relates to new pi3k/akt/m tor inhibitors and their use for the prevention and/or the treatment of a disease selected from the group consisting of: inflammatory diseases, autoimmune diseases, neurodegenerative diseases, cancers, transplant rejection, diseases characterized by a premature aging and tuberous sclerosis.. .
Institut National De La Sante Et De La Recherche Medicale (inserm)


 Chromene derivatives substituted by alkoxide as inhibitors of the tcr-nck interaction patent thumbnailnew patent Chromene derivatives substituted by alkoxide as inhibitors of the tcr-nck interaction
And that present the capacity to inhibit the proliferation of lymphocytes mediated by the nck interaction with tcr, so that the present invention also relates to the use of these compounds for the treatment of diseases or conditions where said interaction triggers a complication such as transplant rejection reactions, immune or autoimmune diseases, inflammatory diseases or proliferative diseases.. .

 Probiotic enhancement of steroid and immune suppressor activity in mammals with chronic diseases patent thumbnailnew patent Probiotic enhancement of steroid and immune suppressor activity in mammals with chronic diseases
This invention relates to use of probiotics, particularly p acidilactici and s boulardii, for use in conjunction with steroids and other immune suppressor agents to ameliorate symptoms of autoimmune diseases, especially disease symptoms arising from the body's production of antibodies against autologous blood cells. The practice of the invention sustains ameliorative response associated with immune suppressor agents while lowering the amount of immune suppressor agents required for treatment..
Imagilin Technology, Llc


 Methods for treating and preventing multiple sclerosis patent thumbnailMethods for treating and preventing multiple sclerosis
We have discovered that lrg-47 (also called p47 gtpase), plays a central role in the pathogenesis of multiple sclerosis, and that inhibition of lrg-47 activity by anti-lrg-47 antibodies or of lrg-47 expression by sirna dramatically reduce the pathology and symptoms of multiple sclerosis. Certain embodiments of the invention are directed to the therapeutic use of anti-lrg-47 antibodies (mouse or rabbit or other antibodies that are humanized or human antibodies to lrg-47, preferably antibodies made against human lrg-47) or sirna or antisense nucleotides that specifically hybridize with the gene or mrna or cdna encoding human lrg-47 to treat or prevent multiple sclerosis and other autoimmune diseases that are t-cell-mediated.
The Trustees Of Columbia University In The City Of New York


Antibody therapeutics that bind ctla4


There is disclosed compositions and methods relating to or derived from anti-ctla4 antibodies. More specifically, there is disclosed fully human antibodies that bind ctla4, ctla4-antibody binding fragments and derivatives of such antibodies, and ctla4-binding polypeptides comprising such fragments.
Sorrento Therapeutics, Inc.


Compositions and methods to image and quantify inflammation


Compositions and methods for assessing inflammation in a subject. The preset disclosure provides compositions for labeling leukocytes with a 19f-containing perfluoropolyether molecule ex vivo.
Celsense, Inc.


Amorphous magnesium-substituted calcium phosphate compositions and their uses


Amorphous magnesium-substituted calcium, phosphate compositions and their medical uses are described, in particular for use in delivering cargo materials, such as cargo molecules or cargo nanoparticles contained in pores of the amorphous magnesium-substituted calcium phosphate to cells of the immune system, for example as therapeutic approaches for the treatment of inflammatory bowel diseases, and in particular crohn's disease, autoimmune diseases, allergy and for therapeutic vaccination.. .
Medical Research Council


Cyclic peptide conjugates and methods of use


The present invention concerns cyclic compounds, compositions comprising the cyclic compounds, linkers, a method of preparing a carrying agent:cyclic compound adduct, a method for treating disorders such as proliferation disorders (e.g., malignancies), bone deficiency diseases, and autoimmune diseases, and a method for suppressing the growth of, or inducing apoptosis in, cells (e.g., malignant cells).. .
Modulation Therapeutics


Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity


A novel fused pyrimidine derivative has an inhibitory activity for tyrosine kinases. A pharmaceutical composition for preventing or treating cancers, tumors, inflammatory diseases, autoimmune diseases, or immunologically mediated diseases contains the fused pyrimidine derivative as an active ingredient..
Hanmi Science Co., Ltd


Bicyclic alkyne derivatives and uses thereof


The present invention relates to certain compounds (e.g., imidazopyrazine, imidazopyridine, imidazopyridazine and imidazpyrimidine compounds) that act as inhibitors of the map kinase interacting kinases mnk2a, mnk2b, mnk1a, and mnk1b. The present invention further relates to pharmaceutical compositions comprising these compounds, and to the use of the compounds for the prevention and treatment of diseases (e.g., proliferative diseases (e.g., cancer), inflammatory diseases, autoimmune diseases, metabolic diseases, and neurodegenerative diseases (e.g.
Agency For Science, Technology And Research


Aza-heteroaryl compounds as pi3k-gamma inhibitors


And pharmaceutically acceptable salts thereof, wherein x, y, z, a, w, r4, r5, and r6 are defined herein, that inhibit the activity of phosphoinositide 3-kinases-gamma (pi3kγ) and are useful in the treatment of diseases related to the activity of pi3kγ including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.. .

Protein-cell conjugate, preparation method and use thereof


The present invention pertains to immunology, biomedicine field, specifically relates to a protein-cell conjugate, which is characterized in that the protein and the cell are coupled via a bifunctional cross-linking agent. The present invention further relates to a preparation method and uses of the protein-cell conjugate.
Cansbio (beijing) Biotechnology Co., Ltd.


Antibodies against pd-1 and uses thereof


The present invention provides antibodies and antigen-binding fragments that specifically bind pd-1 (programmed death 1), thereby modulating immune responses in general, and those mediated by tcr and cd28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer and other immune system disorders..
Medimmune Limited


Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders


Wherein r1a, r1b, r2, r4, r5, r6, r7, r8, w, x, y, z, cy, and the subscript a are as defined herein. The present invention relates to compounds inhibiting autotaxin (npp2 or enpp2), methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and/or treatment of diseases involving fibrotic diseases, proliferative diseases, inflammatory diseases, autoimmune diseases, respiratory diseases, cardiovascular diseases, neurodegenerative diseases, dermatological disorders, and/or abnormal angiogenesis associated diseases by administering the compound of the invention..

Ebi2 modulators


Provided herein are small molecule epstein-barr virus-induced g-protein coupled receptor 2 (ebi2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. Ebi2 is a therapeutic target for the treatment of a variety of diseases or conditions.
Sanford-burnham Medical Research Institute


Prodrugs of monomethyl fumarate (mmf)


The present invention relates to novel compounds for use as a medicament. In particular, the present invention relates to a medicament, preferably in the treatment and/or prevention of systemic diseases, autoimmune diseases, inflammatory diseases, for example multiple sclerosis and psoriasis..
Ratiopharm Gmbh


Substituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis


The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the retinoic acid-related orphan nuclear receptor γt (rorγt)/rorγ. The compounds of the present invention are useful for modulating rorγt)/rorγ activity and for treating diseases or conditions mediated by rorγt)/rorγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as multiple sclerosis (ms), rheumatoid arthritis (ra), inflammatory colitis, psoriasis, copd, pain, obesity, diabetes, dyslipidemia, osteoporosis, asthma, neurodegenerative diseases and cancer..
Arrien Pharmaceuticals Llc


Novel compound useful for the treatement of degenerative and inflammatory diseases


A pyrazolopyridine compound according to formula i, able to inhibit jak is disclosed, as well as pharmaceutically acceptable salts, a solvate thereof, solvates of the pharmaceutically acceptable salts and biologically active metabolites thereof. The compound may be prepared as a pharmaceutical composition, and may be used for the treatment or prophylaxis of a variety of conditions in mammals including humans, and particularly, such conditions as may be associated with aberrant jak activity, including by way of non-limiting example, allergy, inflammatory conditions, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6..

Pidotimod for use in the treatment of inflammation-associated diseases


The present invention relates to a novel use of the active ingredient pidotimod, or its stereoisomers and/or physiologically acceptable salts thereof, to treat inflammation-associated diseases characterized by an aberrant hyperactivation of the non canonical nfkb pathway, such as allergic diseases, autoimmune diseases or other inflammatory diseases based on mechanisms different from allergic or autoimmune.. .
Polichem S.a.


Substituted 2,3-dihydro-1h-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis


The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the retinoic acid-related orphan nuclear receptor γt (rorγt)/rorγ. The compounds of the present invention are useful for modulating rorγt)/rorγ activity and for treating diseases or conditions mediated by rorγt)/rorγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as multiple sclerosis (ms), rheumatoid arthritis (ra), inflammatory colitis, psoriasis, copd, pain, obesity, diabetes, dyslipidemia, osteoporosis, asthma, neurodegenerative diseases and cancer..
Arrien Pharmaceuticals Llc


Method for enhancing therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases


A method for enhancing the therapeutic effect of stem cells on autoimmune diseases, cardiovascular diseases, and/or hematological diseases is provided. The method comprises pre-treating the stem cells with ligustilide to increase the expression of differentiation-promoting genes in the stem cells, increase the expression of homing-promoting genes in the stem cells, and/or decrease the expression of inflammatory genes in the stem cells, wherein the treatment is conducted in a culture medium of the stem cell..
Gwo Xi Stem Cell Applied Technology Co., Ltd.


Methods and compositions for reducing cardiac damage and other conditions


Endoglin has been identified to play a functional role as a regulator of tgfβ1 signaling, particular in tgfβ1-mediated calcineurin expression. The present invention features methods of reducing cardiac damage, particularly in a subject undergoing chemotherapy or radiation therapy by administering a composition that inhibits endoglin activity.
Tufts Medical Center, Inc.


Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein


The present application describes a coding nucleic acid sequence, particularly a messenger rna (mrna), comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal and the use thereof for increasing the expression of an encoded protein. It also discloses its use for the preparation of a pharmaceutical composition, especially a vaccine e.g.
Curevac Ag


Apoptosis-induced agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.


Il4 conjugated to antibodies against extracellular matrix components


A conjugate comprising interleukin-4 (il4) and a specific binding member is disclosed. The specific binding member preferably binds an extra-cellular matrix component associated with neoplastic growth and/or angiogenesis, and the conjugate may be used for targeting il4 to tissues in vivo.
Philogen S.p.a.


Carbazole carboxamide compounds


Disclosed are compounds of formula (i); and salts thereof, wherein: formula (ii); q is: r1 is —c(ch3)2oh, —nhc(=0)c(ch3)3, —n(ch3)2, or —ch2rd; r2 is ci or —ch3; r3 is h, f, or —ch3; ra is h or —ch3; rb is h, f, ci, or —och3 rc is h or f; and rd is —oh, —och3, —nhc(=0)ch3, or formula (iii), also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease..
Bristol-myers Squibb Company


Ido inhibitors


There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (ido), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.. .
Bristol-myers Squibb Company


Mirna based treatment monitoring in autoimmune diseases


The invention relates to methods of determining whether a patient responds to a therapeutic treatment of an autoimmune disease, of monitoring the course of an autoimmune disease in a patient, of determining the risk for a relapse of an autoimmune disease in a patient, and of adjusting the dose of a therapeutic drug applied for therapeutic treatment of an autoimmune disease in a patient. Said methods are based on the determination of the level of at least one mirna in a test sample isolated from the patient.
Comprehensive Biomarker Center Gmbh


Immunogenic peptides and their use in immune disorders


The present invention provides novel peptides and homologues thereof. The peptides of the invention comprise (i) a t-cell epitope of an antigen (self or non-self) with a potential to trigger an immune reaction presented by a class ii major histocompatibility complex (mhc) determinant and recognised by cd4+ t cell more specifically of an allergen or auto-antigen, coupled, optionally through the use of a linker to (ii) an amino acid sequence having a reducing activity, such as a thioreductase sequence.
Katholieke Universiteit Leuven


Substituted tetrahydrocarbazole and carbazoles carboxamide compounds


R1 is f, cl, —cn, or —ch3; r2 is c1 or —ch3; r3 is —c(ch3)2oh or —ch2ch2oh; ra is h or —ch3; each rb is independently f, cl, —ch3, and/or —och3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.

Phosphorylcholine conjugates and uses thereof


The present invention provides phosphorylcholine (pc)-conjugates and pharmaceutical compositions, particularly vaccines comprising same for the prevention or treatment of autoimmune diseases. In particular, the pc-conjugates of the present invention are effective in preventing or treating autoimmune diseases associated with pathological inflammation..
Tel Hashomer Medical Research Infrastructure And Services Ltd.


Human-derived bacteria that induce proliferation or accumulation of regulatory t cells


Species of human-derived bacteria belonging to the clostridia class have been shown to induce accumulation of regulatory t cells (treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases..
School Corporation, Azabu Veterinary Medicine Educational Institution


Human-derived bacteria that induce proliferation or accumulation of regulatory t cells


Species of human-derived bacteria belonging to the clostridia class have been shown to induce accumulation of regulatory t cells (treg cells) in the colon and suppress immune functions. Pharmaceutical compositions containing these bacteria can be used to prevent and treat immune-mediated diseases such as autoimmune diseases..
School Corporation, Azabu Veterinary Medicine Educational Institution


Method for the absolute quantification of naturally processed hla-restricted cancer peptides


The present invention relates to a method for the absolute quantification of naturally processed hla-restricted cancer peptides, i.e. The determination of the copy number of peptide(s) as presented per cell.

Novel anti-fc-gamma receptor iib antibodies and uses thereof


The present invention provides an anti-fcyriib antibodies which, in comparison to prior art antibodies, markedly increase itim phosphorylation of fcyriib and can thus be used for the treatment or prophylaxis of autoimmune diseases.. .

Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.

Substituted benzimidazoles and benzopyrazoles as ccr(4) antagonists


Benzimidazole, benzopyrazole and benzotriazole compounds are provided which bind to ccr(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.. .

Spirocyclic ebi2 modulators


Provided herein are small molecule epstein-barr virus-induced g-protein coupled receptor 2 (ebi2) modulator compounds, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds. In some embodiments, ebi2 is a therapeutic target for the treatment of diseases or conditions such as, but not limited to, autoimmune diseases or conditions, cancer, and cardiovascular disease..

N-cyanomethylamides as inhibitors of janus kinase


The present invention relates to compounds of general formula (1) that are inhibitors of janus kinase (jak), a family of tyrosine kinases that are involved in inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or interferons. In particular, the compound of the invention inhibits jak1 and/or jak2 and/or jak3 sub families.

Antioxidants having aromatic structures reacting with superoxide


Disclosed is a method of treating diseases which are: reactive oxygen species mediated, ischemic or reperfusion-related, or t-cell mediated, including autoimmune diseases. The method is administering a therapeutically effective amount of a formulation wherein the active ingredient includes non-phenolic aromatic structures that are electron deficient and are capable of converting the superoxide radical to o2; and/or of converting superoxide radical to oxygen and hydrogen peroxide, or pharmaceutically acceptable salts of said structures.

Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


Purinone compounds as kinase inhibitors


Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc


Therapeutic compounds


Or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula i, processes for preparing compounds of formula i, intermediates useful for preparing compounds of formula i and therapeutic methods for treating cancer or treating autoimmune diseases or preventing transplant rejection using compounds of formula i..

Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


Methods and compositions for treating autoimmune disorders by targeting kv1.3 ion channels with functionalized lipid-derived nanovesicles


Synthesis and pharmaceutical compositions of antibody-functionalized nanovesicles encapsulating ion channel knockout sirna, and methods of treating autoimmune diseases associated with increased expression and/or hyperactivity of t cells by selectively targeting memory t cells with the nanoparticles, which deliver their sirna cargo into the cytosol of the tm cell thus reducing ion channel expression and decreasing ca2+ influx.. .
North Carolina Agricultural And Technical State University


Use of aptamers in therapy and/or diagnosis of autoimmune diseases


The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of seq id no. 1, seq id no.
Max-delbrueck-centrum Fuer Molekulare Medizin


18f-labelled folates


The present invention is directed towards new 18f-folate radiopharmaceuticals, wherein the fluorine-18 is covalently linked to the aminobenzoyl moiety, which connects the condensed pyrimidine heterocycle to the amino acid portion within folate structures, as well as their precursors and their non-radioactive references, a method of their preparation, as well as their use in diagnosis of a cell or population of cells expressing a folate-receptor and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.. .
Merck & Cie


Benzoimidazol-2-yl pyrimidine modulators of the histamine h4 receptor


Benzoimidazol-2-yl pyrimidines, purification methods for the same, and pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritus.. .
Janssen Pharmaceutica Nv


Clathrin therapeutic for autoimmune diseases


The invention in suitable embodiments is directed to purified clathrin protein therapeutics. In one aspect, one or more purified clathrin protein therapeutic, formed in whole or in part from isolated, synthetic and or recombinant amino acid residues comprising in whole or in part one or more clathrin heavy chain protein and isoforms thereof, forms one or more type of therapeutic agent for treating an autoimmune disease, condition, or disorder in vivo or in vitro..

Apoptotic cell-mediated induction of antigen specific regulatory t-cells for the therapy of autoimmune diseases in animals and humans


The invention provides methods of tolerizing or treating a subject suffering from an autoimmune or autoinflammatory disease or disorder to an antigen associated with the autoimmune disease or disorder. The invention also features kits for carrying out the methods of the invention..
The United States Of America, As Represented By The Secretary, Department Of Health & Human Servic


Methods for treating scleroderma by administering a soluble ctla4 molecule


The present invention relates to compositions and methods for treating autoimmune diseases by administering to a subject a ctla4 molecule that block endogenous b7 molecules from binding their ligands.. .
Bristol-myers Squibb Company


Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.


Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


Pan-elr+ cxc chemokine antibodies


Antibodies are provided that specifically bind seven human elr+ cxc chemokines. The antibodies of the invention are useful for treating various inflammatory/autoimmune diseases, such as inflammatory bowel disease (ibd), plaque psoriasis, and palmoplantar pustulosis; and cancer, such as renal cancer or ovarian cancer..
Eli Lilly And Company


Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


Inducible regulatory t-cell generation for hematopoietic transplants


The present invention provides methods and compositions for converting non-tregs into tregs. The converted tregs are referred to as inducible tregs (itregs).
The Trustees Of The University Of Pennsylvania


Rna-coded antibody


The present application describes an antibody-coding, non-modified or modified rna and the use thereof for expression of this antibody, for the preparation of a pharmaceutical composition, in particular a passive vaccine, for treatment of tumours and cancer diseases, cardiovascular diseases, infectious diseases, autoimmune diseases, virus diseases and monogenetic diseases, e.g. Also in gene therapy.
Curevac Ag


Ido inhibitors


There are disclosed compounds of formula (i) that modulate or inhibit the enzymatic activity of indoleamine 2,3-di-oxygenase (ido), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or autoimmune diseases utilizing the compounds of the invention.. .
Bristol-myers Squibb Company


Compositions and methods for treating cancer and other diseases


Aptamers and improved aptamers are provided with enhanced efficacy for binding to target molecules in vivo or for treating cancer or other diseases. Such improvements in aptamers are provided that enhance in vivo efficacy such as binding to the target molecule or enhancing anti-cancer activity.
Memorial Sloan Kettering Cancer Center


Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor


The present invention is based, in part, on the identification of novel human anti-pd-1, pd-l1, and pd-l2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating pd-1, pd-l1, and/or pd-l2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-pd-1, pd-l1, and pd-l2 antibodies described herein..
Emory University


Fcrn-specific human antibody and composition for treatment of autoimmune diseases


The present invention relates to a human antibody specific for fcrn that is a receptor with a high affinity for igg, a production method thereof, a composition for treating autoimmune disease, which comprises the antibody, and a method of treating and diagnosing autoimmune disease using the same. The fcrn-specific antibody according to the present invention can bind to fcrn non-competitively with igg or the like to reduce serum auto-antibody levels, and thus can be used for the treatment of autoimmune diseases..
Hanall Biopharma Co., Ltd.


Novel compounds and uses thereof


The present invention provides novel compounds of any one of formulae (i)-(iv), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of any one of formulae (i)-(iv) and pharmaceutical compositions thereof that are mucus penetrating.
Kala Pharmaceuticals, Inc.


Sphingoglycolipid analogues


The invention relates to sphingoglycolipid analogues which are useful in treating or preventing diseases and conditions such as those relating to infection, atopic disorders, autoimmune diseases or cancer.. .
Victoria Link Limited


Detection and treatment of autoimmune disorders


Disclosed herein are methods of treatment of autoimmune diseases such as systemic lupus erythematosus (sle) as well as clinical assays for detection of autoimmune disease activity in patients utilizing a pd1 ligand.. .
Seattle Children's Hospital


Method for obtaining immuno-suppressive dendritic cells


The present invention relates to methods for producing immuno-suppressive dendritic cells. The present invention further relates to the use of such cells for treating patients suffering from autoimmune diseases, hypersensitivity diseases, rejection on solid-organ transplantation and/or graft-versus-host disease..
Yale University


Her2/neu-specific antibodies and methods of using same


This invention relates to antibodies that specifically bind her2/neu, and particularly chimeric 4d5 antibodies to her2/neu, which have reduced glycosylation as compared to known 4d5 antibodies. The invention also relates to methods of using the 4d5 antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.


Interleukin 15 (il-15) antagonists and uses thereof for the treatment of autoimmune diseases and inflammatory diseases


The present relates to interleukin 15 (il-15) antagonists and uses thereof, in particular for the treatment of autoimmune diseases and inflammatory diseases. In particular, the present invention relates to an il-15 mutant polypeptide having the amino acid sequence as set forth in seq id no:1 wherein the leucine residue at position 45 is substituted by an aspartic acid residue, the asparagines residue at position 65 is substituted by a lysine residue and the leucine residue at position 69 is substituted by an arginine residue.
Universite D'angers


Composition of mesenchymal stem cells


This invention relates in general to a mesenchymal stem cell (msc) therapy. This invention further relates to the isolation and applications of gingiva derived mesenchymal stem cells.
University Of Southern California


Anti-tnf- / anti-il-23 bispecific antibodies


Bispecific antibodies are provided that bind tumor necrosis factor alpha (tnfα) and the p19 subunit of interleukin-23 (il-23p19) and are characterized as having high affinity and strong simultaneous neutralizing properties to both tnfα and il-23. The bispecific antibodies of the invention are useful for treating various autoimmune diseases including inflammatory bowel disease, such as crohn's disease and ulcerative colitis, axial spondyloarthropathy, rheumatoid arthritis and psoriatic arthritis..
Eli Lilly And Company


Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..

Inhibitors of cyclin-dependent kinase 7 (cdk7)


The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, lymphoma, melanoma, multiple myeloma, breast cancer, ewing's sarcoma, osteosarcoma, brain cancer, neuroblastoma, lung cancer), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject.
Dana-farber Cancer Institute, Inc.


Methods for the treatment or prevention of systemic sclerosis


The disclosure is in the field of molecular immunology, more in particular, in the field of the prevention or treatment of autoimmune diseases, more in particular, systemic sclerosis or scleroderma. The disclosure is based on the observation that ssc patients have an elevated plasma level of cxcl4.
Stichting Katholieke Universiteit


Immunologically active polypeptide


Disclosed are immunomodulatory polypeptides that behave as weak tlr2 and tlr4 agonists and as potent competitive antagonists of natural pathogenic ligands for human and murine tlr2 and tlr4, that identify a subset of neutrophils in human peripheral blood leukocytes, and that elicit an unusual induced cytokine profile. Also disclosed are compositions comprising such polypeptides, compositions comprising antibodies that specifically bind to such polypeptides, and methods of using the same, including for treating sepsis or reducing the severity or likelihood of occurrence of sepsis, in cancer treatment, in the treatment of autoimmune diseases, in organ transplantation and for reducing graft rejection, for promoting fertility, and for identifying a neutrophil subset and/or other cellular subset including by flow cytometry.
Institute Of Arthritis Research, Llc


Indole carboxamide compounds


Or a salt thereof, wherein: x is cr4 or n; r1, r2, r3, r4, and a are defined herein. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.

Detection of gluten-specific t-cells


The present invention relates to compositions and methods for visualizing disease-specific t-cells. In particular, the present invention relates to compositions and methods for use in the diagnosis, monitoring of progression, monitoring of response to therapy, and selection of patients for therapy of autoimmune diseases characterized by selective expansion of disease-specific effector memory t-cells..

Method for the analysis of n-glycans attached to immunoglobulin g from human blood plasma and its use


From the results of the analysis, glycan age index (gai) is calculated, and it is useful for: prediction of biological age of a tested individual; monitoring efficacy of methods that slow down the ageing process; monitoring progression of diseases that are developed as a result of the ageing process advancement, like: inflammatory diseases (including atherosclerosis), autoimmune diseases, tumours, diabetes, arthritis, osteoporosis, and alzheimer disease; and evaluation of overall condition/health of a body.. .

Monomers and oligonucleotides comprising cycloaddition adduct(s)


In one embodiment, the invention relates compounds and processes for conjugating ligand to oligonucleotide. The invention further relates to methods for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, cancers, allergies, autoimmune diseases, immunodeficiencies and immunosuppression..

Highly concentrated formulations of soluble fc receptors


The present invention relates to novel formulations of soluble fc receptors and especially to formulations containing high concentrations of soluble fcγriib receptor. The invention further relates to the use of such formulations as pharmaceutical compounds for the treatment of autoimmune diseases, infections and other conditions where the immune system is involved..
Suppremol Gmbh


Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions


Dopamine reuptake inhibitors, and their analogs, are disclosed for treating and delaying the progression of autoimmune diseases.. .
Caliper Life Sciences, Inc.


Bispecific constructs and their use in the treatment of various diseases


The present invention relates to bispecific constructs that specifically bind to immune effector cells and, simultaneously, to il23r-carrying target cells, as well as nucleic acids, vectors, host cells, pharmaceutical compositions, and methods of production and use thereof, including such bispecific constructs for use in treating inflammatory and/or autoimmune diseases and/or cancer.. .
Numab Ag




Autoimmune Diseases topics:
  • Immune Diseases
  • Autoimmune Disease
  • Autoimmune Diseases
  • Immune Disease
  • Autoimmune
  • Rheumatoid Arthritis
  • Antibodies
  • Proliferative
  • Nucleotide
  • Antagonist
  • Infectious Diseases
  • Inflammatory Disease
  • Infectious Disease
  • Infectious
  • Multiple Sclerosis


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Autoimmune Diseases for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Diseases with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.873

    5554

    2 - 1 - 101